Emerging drugs for the treatment of attention-deficit hyperactivity disorder (ADHD)
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Attention-deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder affecting up to 5.3% of children and 2.5% of adults depending on the country considered. Current pharmacological treatments for ADHD are based on stimulant or non-stimulant medications, targeting dopaminergic and noradrenergic systems in the frontal cortex and dopaminergic system in the basal ganglia. These drugs are effective and safe for the majority of patients, whereas about 20% of treated patients do not tolerate current therapies or experience insufficient efficacy. The adequate treatment of ADHD is necessary to allow a proper social placement and prevent the acquisition of additional, more severe, comorbidities. AREAS COVERED: We conducted a review of the scientific literature and of unpublished/ongoing clinical trials to summarize the advances made in the last 10 years (2010-2020) for the pharmacological treatment of ADHD. We found many pharmacological mechanisms beyond dopaminergic and noradrenergic ones have been investigated in patients. EXPERT OPINION: Some emerging drugs for ADHD may be promising as add-on treatment especially in children, amantadine to enhance cognitive functions and tipepidine for hyperactivity/impulsivity. Stand-alone emerging treatments for ADHD include viloxazine and dasotraline, which will soon have more clinical data available to support market access requests.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The worldwide prevalence of ADHD: a systematic review and metaregression analysis
Polanczyk, G., de Lima, M. S., Horta, B. L., Biederman, J., & Rohde, L. A. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.6.942 · Cited by 5,346
Polanczyk, G. V., Salum, G. A., Sugaya, L. S., Caye, A., & Rohde, L. A. (2015) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12381 · Cited by 3,990 · cited 1×
“[2,3] suggest that ADHD occurs in most cultures in about 5.”
BackgroundPrevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis
Simon, V., Czobor, P., Bálint, S., Mészáros, Á., & Bitter, I. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.048827 · Cited by 1,601
Attention-deficit/hyperactivity disorder
Faraone, S. V., Asherson, P., Banaschewski, T., Biederman, J., Buitelaar, J. K., Ramos-Quiroga, J. A., Rohde, L. A., Sonuga-Barke, E. J. S., Tannock, R., & Franke, B. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.20 · Cited by 1,479
Neuronal nicotinic receptors: from structure to pathology
Gotti, C., & Clementi, F. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.09.006 · Cited by 970 · cited 1×
“Nicotinic receptors of the α4β2 subtype (nAChR α4β2) are found only in some regions of the central nervous system (cortex, hippocampus, striatum and thalamus) implicated with attention [28] and specific nAChR α4β2 agonists were demonstrated to improve attention and cognitive performance in healthy adults [29].”
BackgroundAttention-deficit hyperactivity disorder
Posner, J., Polanczyk, G. V., & Sonuga-Barke, E. (2020) · The Lancet · doi:10.1016/s0140-6736(19)33004-1 · Cited by 835
Posner, J., Nagel, B. J., Maia, T. V., Mechling, A., Oh, M., Wang, Z., & Peterson, B. S. (2011) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2011.05.010 · Cited by 137
Sobel, L. J., Bansal, R., Maia, T. V., Sanchez, J., Mazzone, L., Durkin, K., Liu, J., Hao, X., Ivanov, I., Miller, A., et al. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09091259 · Cited by 105
Yuen, E. Y., & Yan, Z. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5050-08.2009 · Cited by 81
Cunill, R., Castells, X., Tobias, A., & Capellà, D. (2013) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3473 · Cited by 70
Cited by
Dopamine, Immunity, and Disease
Channer, B., Matt, S. M., Nickoloff-Bybel, E. A., Pappa, V., Agarwal, Y., Wickman, J., & Gaskill, P. J. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000618 · Cited by 308
Annual Research Review: Perspectives on progress in ADHD science – from characterization to cause
Sonuga‐Barke, E. J. S., Becker, S. P., Bölte, S., Castellanos, F. X., Franke, B., Newcorn, J. H., Nigg, J. T., Rohde, L. A., & Simonoff, E. (2023) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.13696 · Cited by 157
Nazarova, V. A., Sokolov, A. V., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1066988 · Cited by 111
“The main reason for drug discontinuation was lack of efficacy or safety (e.g., bradanicline, vortioxetine, bavisant, PF-03654746, NS-2359, AZD1446) (Learned et al., 2012; Haig et al., 2014; Pozzi et al., 2020).”
BackgroundInfluentialViloxazine: Pediatric First Approval
Lamb, Y. N. (2021) · Pediatric Drugs · doi:10.1007/s40272-021-00453-3 · Cited by 29
Abdi Dezfouli, R., Akbariforoud, S., & Esmaeilidezfouli, E. (2024) · Middle East Current Psychiatry · doi:10.1186/s43045-024-00405-w · Cited by 4
“Moreover, while one recent comprehensive review suggested memantine as an alternative [50], another study did not recommend memantine and galantamine as valid alternative therapies [49].”
Background
Metadata
- Authors
- Pozzi, M., Bertella, S., Gatti, E., Peeters, G. G. A. M., Carnovale, C., Zambrano, S., & Nobile, M.
- Venue
- Expert Opinion on Emerging Drugs
- Publisher
- Informa UK Limited
- Published
- 2020-09-25
- Volume
- 25
- Issue
- 4
- Pages
- 395-407
- ISSN
- 1472-8214 (ISSN-L)
- 1744-7623
- OpenAlex
- W3087659545
- Cited by
- 55
- References
- 14
- FWCI
- 4.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Emerging drugs for the treatment of attention-deficit hyperactivity disorder (ADHD). https://app.cochat.ai/papers/10.1080/14728214.2020.1820481
- The paper
- Pozzi, M., Bertella, S., Gatti, E., Peeters, G. G. A. M., Carnovale, C., Zambrano, S., & Nobile, M. (2020). Emerging drugs for the treatment of attention-deficit hyperactivity disorder (ADHD). Expert Opinion on Emerging Drugs. https://doi.org/10.1080/14728214.2020.1820481
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.